22:14 , Aug 16, 2019 |  BC Extra  |  Company News

Ahead of FDA decisions on one antibiotic, Nabriva plans resubmission of another

As it awaits FDA's decisions on twin NDAs for lefamulin, Nabriva said it plans to resubmit an NDA early next quarter for another one of its antibiotics following a complete response letter this year. Nabriva...
00:12 , Jun 15, 2019 |  BC Extra  |  Company News

June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more

ISS weighs in on Weber  Institutional Shareholder Services recommended Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) shareholders oppose President and CEO Christophe Weber at the June 27 shareholder meeting because “top management is responsible for the...
23:45 , Apr 16, 2019 |  BC Extra  |  Company News

Achaogen files for bankruptcy amid continued headwinds for antibiotic developers

Following regulatory headwinds and what it called very limited uptake of its sole marketed antibiotic, Achaogen filed for Chapter 11 bankruptcy late Monday. It is one of several antibiotic companies that have lost over half...
13:15 , Apr 1, 2019 |  BC Innovations  |  Emerging Company Profile

Arixa: Breaking resistance with oral beta lactamase inhibitors

Arixa has made an IV antibiotic oral with prodrug chemistry. Arixa Pharmaceuticals Inc. is modifying diazabicyclooctanes, a class of β-lactamase inhibitors that suffer from poor absorption across the GI tract, for use in combination with...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
22:52 , Oct 26, 2018 |  BC Extra  |  Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

Immunology and oncology company Principia Biopharma Inc. (NASDAQ:PRNB) hired Dolca Thomas as CMO. She succeeds Steve Gourlay, who will remain as a senior medical adviser through mid-2019. Thomas was VP and global head of translational...
17:08 , Oct 19, 2018 |  BC Week In Review  |  Company News

Tetraphase launches Xerava in the U.S.

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) launched Xerava eravacycline in the U.S. to treat complicated intra-abdominal infections (cIAIs) in adults at a wholesale acquisition cost (WAC) of $175 per day. According to its U.S. label, Xerava is...
01:14 , Oct 6, 2018 |  BioCentury  |  Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
19:57 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

Tetraphase's Xerava antibiotic gets EU approval

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) said the European Commission approved Xerava eravacycline to treat complicated intra-abdominal infections (cIAIs) in adults. The company plans to begin a phased EU launch of the IV broad-spectrum fluorocycline antibiotic next...
18:18 , Sep 28, 2018 |  BC Week In Review  |  Company News

Everest adds another antibiotic to pipeline through VenatoRx deal

C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) will receive exclusive rights from VenatoRx Pharmaceuticals Inc. (Malvern, Pa.) to develop and commercialize VNRX-5133 in combination with cefepime. The deal covers Greater China, South Korea and Southeast Asia...